Firma immatics biotechnologies, Autor bei News-Research

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

24. Oktober 202324. Oktober 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actengine, cancer, cmc, griffin, ima203, ima203cd8, immatics, monotherapy, patients, prame, rmat, sep, statements, tcr, with

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities underway with […]

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

11. September 202311. September 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged ??royalty??, cancer, hla, ima203, immatics, patients, prame, quest, Royalties, statements, tcer, tcr, vaccine, vaccines, with

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology for the development of novel cancer vaccines […]

Moderna und Immatics geben strategische Multi-Plattform-Kollaboration zur Entwicklung innovativer Onkologie Therapeutika bekannt

11. September 202311. September 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged aussagen, discovery, hla, ima203, immatics, mrna, patienten, prame, research, rna, securities, studie, tcr, zukunftsgerichtete, zukunftsgerichteten

Kollaboration kombiniert führende Technologien zur Entwicklung bahnbrechender, in vivo exprimierter mRNA TCER®-Moleküle Die Unternehmen werden zur Entwicklung neuartiger Krebsimpfstoffe Immatics Target-Discovery-Plattform XPRESIDENT® und Modernas mRNA-Technologie nutzen Die Kollaboration umfasst die Untersuchung von […]

Immatics Announces Second Quarter 2023 Financial Results and Business Update

17. August 2023 Firma immatics biotechnologiesPosted in Finanzen / BilanzenTagged actengine, breast, cancer, ima203, ima203cd8, ima401, ima402, immatics, investorsimmaticscom, market, prame, statements, tcer, tcr, with

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an […]

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

10. August 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actengine, cancer, domain, dosing, hla, ima203, ima402, immatics, patients, prame, statements, syndrome, tcer, tcr, with

TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient enrollment for IMA402 Phase 1/2 trial underway The trial will evaluate safety, tolerability, […]

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

2. Mai 20232. Mai 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actengine, gtima203, ima203, immatics, ltem, ltli, ltp, ltstrong, ltsup, noopener, noreferrer, prame, quotjustify, quotnofollow, statements

<ul type="disc"> <li>Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME</li> <li>Objective response rate (ORR): 64% […]

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

2. Mai 20232. Mai 2023 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged cancer, cell, clinical, discovery, immatics, patients, Payment, report, Royalties, statements, tcr, tcrs, therapy, with, xpresident

Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop […]

Immatics Announces Full Year 2022 Financial Results and Corporate Update

21. März 202321. März 2023 Firma immatics biotechnologiesPosted in Finanzen / BilanzenTagged actengine, cancer, crispr, delta, editas, ima203, ima203cd8, ima401, ima402, immatics, prame, statements, tcer, tcr, with

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a […]

Immatics Announces Third Quarter 2022 Financial Results and Business Update

17. November 202217. November 2022 Firma immatics biotechnologiesPosted in Finanzen / BilanzenTagged actengine, ima203, ima203cd8, ima402, immatics, ltem, ltli, ltp, ltstrong, ltsup, noopener, noreferrer, prame, quotjustify, quotnofollow

Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective response rate (cORR) of 50% (6/12) at or above target dose across Phase 1a and Phase […]

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

10. Oktober 202210. Oktober 2022 Firma immatics biotechnologiesPosted in Forschung und EntwicklungTagged actengine, gtima203, ima203, ima203cd8, immatics, ltem, ltli, ltp, ltstrong, ltsup, noopener, noreferrer, quotjustify, quotnofollow, statements

Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression Update covers data […]